Select Publications

De Gramont A et al. Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol 2007a;34(2 Suppl 1):37-40. Abstract

De Gramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of 6 years. Proc ASCO 2007b;Abstract 4007.

De Gramont A et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 2007c;25(22):3224-9. Abstract

Grothey A et al. Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE). Proc ASCO 2007;Abstract 4036.

Hecht JR et al. An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (Bev) for metastatic colorectal cancer (MRCR). Presentation. World Congress on Gastrointestinal Cancer 2007. No abstract available

Kuebler JP et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 2007;25(16):2198-204. Abstract

Maindrault-Goebel F et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. Proc ASCO 2007;Abstract 4013.

Maindrault-Goebel F et al. OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. Proc ASCO 2006;Abstract 3504.

Schmoll HJ et al. Final safety findings from a randomized phase III trial of capecitabine + oxaliplatin (XELOX) vs bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer. Proc ASCO 2006;Abstract 3569.

Tournigand C et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer — A GERCOR study. J Clin Oncol 2006;24(3):394-400. Abstract

Tyagi P, Grothey A. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: The NO16966 trial. Clin Colorectal Cancer 2006;6(4):261-4. Abstract

Wainberg Z, Hecht JR. A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006;5(5):363-7. Abstract

 

 

 

 

 

Table of Contents

Top of Page